Lateral Flow Assays Market Size

Lateral Flow Assays Market size was valued at USD 12.76 billion in 2024 and is expected to cross USD 32.52 billion by the end of 2037, registering more than 7.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of lateral flow assays is estimated at USD 13.53 billion.

The growth of the market is mainly due to the increasing prevalence of infectious diseases. According to the World Health Organization (WHO), infectious diseases are the leading cause of death worldwide, accounting for about 25% of all deaths worldwide.

Increasing demand for diagnostic test products that use lateral flow technology for the detection of diseases, is further predicted to drive the lateral flow assays market. In 2020, an estimated 38 million people were living with HIV/AIDS worldwide, with 1.5 million new infections and 690,000 deaths. Tuberculosis (TB) remains one of the top 13th causes of death globally with about 10.6 million new cases and 1.6 million deaths in 2021.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of lateral flow assays is estimated at USD 13.53 billion.

The lateral flow assays market size was valued at USD 12.76 billion in 2024 and is expected to cross USD 32.52 billion by the end of 2037, registering more than 7.4% CAGR during the forecast period i.e., between 2025-2037. The growing prevalence of infectious diseases and spiking healthcare spending will propel the market growth.

North America industry is assumed to hold a notable share of 26% by 2037, driving the development of new and innovative transverse flow analysis technologies in the region.

The major players in the market include Abbott Laboratories, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, F.Hoffmann-La Roche AG, QIAGEN N.V., Siemens Healthineers AG, Thermo Fisher Scientific, Inc., Merck kGaA, PerkinElmer Inc.

Lateral Flow Assays Market Size